SecBot SecBot
SECBOTREPLAY Home › Report › AXGN

AXGN · Prostate market launch

Axogen, Inc. · 8-K filed Nov 9, 2026 at 08:52 ET

At the news

BULLISHIMPACT 5/10

8-K filed Nov 9, 2026 at 08:52 ET

Axogen hosted an investor event announcing its decision to launch into the prostate nerve reconstruction market using its Avance nerve allograft. The presentation cited a $754 million total addressable market and clinical data showing improved erectile function recovery versus historical controls. No financial results or guidance were provided.

  • Axogen announced a decision to launch into the prostate nerve reconstruction market
  • Total addressable market estimated at $754 million with a weighted ASP of ~$7,000 per procedure
  • Clinical data from 117 patients with at least 6 months follow-up showed ~80% had better than expected erectile function and >95% return of continence
  • Over 220 patients have been reconstructed with Avance nerve allograft in prostate procedures

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access